(Reuters) - Eli Lilly and Co said on Monday it would buy Loxo Oncology Inc for about $8 billion in cash.
The offer of $235 per share in cash represents a premium of about 68 percent to Loxo's Friday close.
In November, a Loxo drug found to be effective against a wide variety of cancers driven by a single, rare genetic mutation won U.S. approval.
(Reporting by Ankur Banerjee in Bengaluru; Editing by Saumyadeb Chakrabarty)
Disclaimer: No Business Standard Journalist was involved in creation of this content
